We are joining the ISTH Congress 2026 in Paris, France, on 11–15 July 2026.

As one of the premier global congresses in thrombosis, haemostasis, and vascular biology, the ISTH Congress brings together clinicians, researchers, and industry leaders to explore cutting‑edge science, innovative therapies, and advances in clinical practice that shape the future of haemostatic medicine.

Representing Richmond Pharmacology:

  • Dr Jörg Taubel, Chief Executive Officer

Our Focus at the Congress

  • Advances in thrombosis and haemostasis research
  • Innovative therapeutic strategies for coagulation disorders
  • Early‑phase clinical development pathways for haematology and vascular medicines
  • Biomarkers, precision medicine, and emerging diagnostic approaches
  • Cross‑sector collaboration between academia, biotech, and clinical research organisations

Connect With Us

If you are attending the ISTH Congress 2026 and would like to explore collaboration or development opportunities:

📧 fasteranswers@richmondpharmacology.com

Find out more here: ISTH Congress | Thrombosis and Hemostasis Conference

Latest news

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
Read more

Upcoming Event

ESC Congress 2026

28 - 31 August 2026
Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.
View event